Clinical Oversight Review Board-FAST (CORB-FAST) Criteria for Prescribing / Criteria-Based Consultation (CBC) Criteria for Coverage

Apomorphine SL (Kynmobi)

Notes:

 A time when a patient's medications are not working well, causing an increase in Parkinson's disease symptoms, such as tremor and difficulty walking.

Initiation (new start) criteria and criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Nonformulary apomorphine SL (Kynmobi) will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed by neurologist with expertise in diagnosis and management of Parkinson's disease
- Patient experiences "OFF" episodes^ that significantly interfere with functioning
- Patient experiences "OFF" episodes^ that are not response to extra, as needed oral doses of carbidopa/levodopa or levodopa
- Patient is currently taking carbidopa/levodopa immediate release or controlled release 5 or more times per day <u>OR</u> is currently taking carbidopa/levodopa extended release (Rytary).

<u>Criteria for new members entering Kaiser Permanente already taking the</u>
<u>medication who have not been reviewed previously</u>: Non-formulary apomorphine SL
(Kynmobi) will be covered on the prescription drug benefit for <u>12 months</u> when the following criteria are met:

Patient is currently stable on medication

<u>Continued use criteria for patients stable on the medication</u>: Non-formulary apomorphine SL (Kynmobi) will continue to be covered on the prescription drug benefit for <u>12 months</u> when the following criteria are met:

- Continues to be prescribed by neurologist with expertise in diagnosis and management of Parkinson's disease
- Patient has been seen by neurologist within the past 12 months

kp.org

Revised: 03/11/21 Effective: 05/20/21 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest

